Ramesh V, Kaushal Himanshu, Mishra Ashwani Kumar, Singh Ruchi, Salotra Poonam
Department of Dermatology, VMMC & Safdarjung Hospital, New Delhi, 110029, India.
National Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi, 110029, India.
BMC Public Health. 2015 Oct 26;15:1092. doi: 10.1186/s12889-015-2424-8.
Patients with Post kala-azar dermal leishmaniasis (PKDL) are considered a reservoir of Leishmania donovani. It is imperative to identify and treat them early for control of visceral leishmaniasis (VL), a current priority in the Indian subcontinent. We explored trends in clinico-epidemiological features of PKDL cases over last two decades, for improving management of the disease.
Clinically suspected cases were diagnosed with rK39 strip test followed by parasitological confirmation by microscopy and/or PCR/qPCR in skin tissue/slit aspirates. Patients were treated with antimonials till 2008 and subsequently with miltefosine.
The study indicated higher incidence of PKDL cases in areas of high endemicity for VL, with 20 % cases reporting no history of VL. Approximately 26 % cases of PKDL were initially misdiagnosed at primary health centers. Duration between onset of PKDL and diagnosis was above 12 months in 80 % cases. Diagnostic sensitivity was 32-36 % with microscopy and 96-100 % with PCR/qPCR. Compliance to treatment was over 85 % with miltefosine while 15 % with antimonials. Relapse rate with miltefosine was up to 13.2 %.
PKDL patients tend to delay reporting and are often misdiagnosed. Confirmatory diagnosis using minimally invasive skin slit aspirate samples would help overcome such issues. There was a paradigm shift in compliance with miltefosine; however, increasing relapse rate indicated the need for newer therapies with oral formulations.
黑热病后皮肤利什曼病(PKDL)患者被视为杜氏利什曼原虫的储存宿主。为控制内脏利什曼病(VL)(这是印度次大陆当前的优先事项),必须尽早识别并治疗这些患者。我们探讨了过去二十年中PKDL病例的临床流行病学特征趋势,以改善该疾病的管理。
临床疑似病例通过rK39试纸条检测进行诊断,随后通过皮肤组织/皮肤刮片抽吸物的显微镜检查和/或PCR/qPCR进行寄生虫学确诊。2008年之前患者接受锑剂治疗,之后使用米替福新进行治疗。
研究表明,在VL高流行地区PKDL病例的发病率较高,20%的病例报告无VL病史。约26%的PKDL病例最初在初级卫生中心被误诊。80%的病例中,PKDL发病至诊断的时间超过12个月。显微镜检查的诊断敏感性为32 - 36%,PCR/qPCR为96 - 100%。米替福新治疗的依从率超过85%,而锑剂治疗为15%。米替福新的复发率高达13.2%。
PKDL患者往往延迟就诊且常被误诊。使用微创皮肤刮片抽吸样本进行确诊有助于克服此类问题。在米替福新的依从性方面发生了范式转变;然而,复发率不断上升表明需要新的口服制剂疗法。